Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis

The development of psoriasis and alopecia areata (AA) is multifactorial. The interleukin-17 (IL-17) cytokine is believed to be associated with the pathophysiology of both diseases. This case report demonstrates a 64-year-old female patient who experienced a new onset of AA after the initiation of IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Esther, Thomson, Olivia, Smith, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292069/
https://www.ncbi.nlm.nih.gov/pubmed/37378242
http://dx.doi.org/10.7759/cureus.38986
_version_ 1785062810925924352
author Choi, Esther
Thomson, Olivia
Smith, David
author_facet Choi, Esther
Thomson, Olivia
Smith, David
author_sort Choi, Esther
collection PubMed
description The development of psoriasis and alopecia areata (AA) is multifactorial. The interleukin-17 (IL-17) cytokine is believed to be associated with the pathophysiology of both diseases. This case report demonstrates a 64-year-old female patient who experienced a new onset of AA after the initiation of IL-17A inhibitor, secukinumab, for the treatment of her psoriasis. To our knowledge, there are only three case reports specifically discussing IL-17A inhibitors and AA. This case report highlights a potential rare but significant side effect of IL-17A inhibitors. 
format Online
Article
Text
id pubmed-10292069
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102920692023-06-27 Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis Choi, Esther Thomson, Olivia Smith, David Cureus Dermatology The development of psoriasis and alopecia areata (AA) is multifactorial. The interleukin-17 (IL-17) cytokine is believed to be associated with the pathophysiology of both diseases. This case report demonstrates a 64-year-old female patient who experienced a new onset of AA after the initiation of IL-17A inhibitor, secukinumab, for the treatment of her psoriasis. To our knowledge, there are only three case reports specifically discussing IL-17A inhibitors and AA. This case report highlights a potential rare but significant side effect of IL-17A inhibitors.  Cureus 2023-05-13 /pmc/articles/PMC10292069/ /pubmed/37378242 http://dx.doi.org/10.7759/cureus.38986 Text en Copyright © 2023, Choi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Choi, Esther
Thomson, Olivia
Smith, David
Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title_full Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title_fullStr Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title_full_unstemmed Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title_short Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
title_sort alopecia areata after initiation of secukinumab therapy for plaque psoriasis
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292069/
https://www.ncbi.nlm.nih.gov/pubmed/37378242
http://dx.doi.org/10.7759/cureus.38986
work_keys_str_mv AT choiesther alopeciaareataafterinitiationofsecukinumabtherapyforplaquepsoriasis
AT thomsonolivia alopeciaareataafterinitiationofsecukinumabtherapyforplaquepsoriasis
AT smithdavid alopeciaareataafterinitiationofsecukinumabtherapyforplaquepsoriasis

Ejemplares similares